Optimal Sampling Times for Bayesian Estimation of the Pharmacokinetic Parameters of Nortriptyline During Therapeutic Drug Monitoring

被引:0
|
作者
Yann Merlé
France Mentré
机构
[1] INSERM U436,
[2] CHU Pitié-Salpêtrière,undefined
关键词
nortriptyline; Bayesian design; Bayesian estimation; information criterion; optimal sampling times; therapeutic drug monitoring;
D O I
暂无
中图分类号
学科分类号
摘要
Sampling times for Bayesian estimation of the pharmacokinetic parameters of an antidepressant drug, nortriptyline, during its therapeutic drug monitoring were optimized. Our attention was focused on designs including a limited number of measurements: one, two, and three sample designs in which sampling times had to be chosen between 0 and 24 hr after the last intake of a test-dose study. The optimization was conducted in four groups of patients defined by their gender and the administration or not of concomitant drugs inhibiting the metabolism of nortriptyline. The Bayesian design criterion was defined as the expected information provided by an experiment. A stochastic approximation algorithm, the Kiefer–Wolfowitz algorithm, was used for the criterion maximization under experimental constraints. Results showed that optimal Bayesian sampling times differ between patients in monotherapy and polytherapy. For one-sample designs the measurements have to be performed either at the lower (0 hr) or at the upper (24 hr) bound of the admissible interval. Replications were often found for 2- and 3-point designs. Other sampling designs can lead to criterion close to the optimum and can therefore be performed without great loss of information. In contrast, we found that several designs lead to low values of the information criterion, which justifies the approach.
引用
收藏
页码:85 / 101
页数:16
相关论文
共 50 条
  • [1] Optimal sampling times for Bayesian estimation of the pharmacokinetic parameters of nortriptyline during therapeutic drug monitoring
    Merlé, Y
    Mentré, F
    JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1999, 27 (01): : 85 - 101
  • [2] CHOOSING OPTIMAL SAMPLING TIMES FOR THERAPEUTIC DRUG-MONITORING
    SCHUMACHER, GE
    CLINICAL PHARMACY, 1985, 4 (01): : 84 - 92
  • [3] Bayesian estimation of pharmacokinetic parameters: an important component to include in the teaching of clinical pharmacokinetics and therapeutic drug monitoring
    Brocks, Dion
    Hamdy, Dalia
    RESEARCH IN PHARMACEUTICAL SCIENCES, 2020, 15 (06) : 503 - 514
  • [4] Pharmacokinetic Modeling and Optimal Sampling Strategies for Therapeutic Drug Monitoring of Rifampin in Patients with Tuberculosis
    Sturkenboom, Marieke G. G.
    Mulder, Leonie W.
    de Jager, Arthur
    van Altena, Richard
    Aarnoutse, Rob E.
    de Lange, Wiel C. M.
    Proost, Johannes H.
    Kosterink, Jos G. W.
    van der Werf, Tjip S.
    Alffenaar, Jan-Willem C.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (08) : 4907 - 4913
  • [5] Daptomycin Therapeutic drug monitoring: Evaluation of simplified sampling strategies for Bayesian AUC estimation
    Tuloup, V.
    Tarrico, A.
    Heitzmann, J.
    Gagnieu, M. C.
    Ferry, T.
    Goutelle, S.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2022, 36 : 157 - 158
  • [6] APPROPRIATENESS OF SAMPLING TIMES FOR THERAPEUTIC DRUG-MONITORING
    MASON, GD
    WINTER, ME
    AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1984, 41 (09): : 1796 - 1801
  • [7] INFLUENCE OF SAMPLING TIMES OF DRUG LEVELS IN BAYESIAN PHARMACOKINETIC CONTROL OF DRUG-THERAPY
    PECK, CC
    CHEN, BC
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1985, 37 (02) : 220 - 220
  • [8] NONLINEAR KINETICS OF NORTRIPTYLINE IN RELATION TO NORTRIPTYLINE CLEARANCE AS OBSERVED DURING THERAPEUTIC DRUG-MONITORING
    JERLING, M
    ALVAN, G
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 46 (01) : 67 - 70
  • [9] OPTIMAL SAMPLING TIMES FOR PHARMACOKINETIC EXPERIMENTS
    DARGENIO, DZ
    JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1981, 9 (06): : 739 - 756
  • [10] OPTIMAL SAMPLING TIMES FOR PHARMACOKINETIC STUDIES
    DARGENIO, DZ
    SCHUMITZKY, A
    RODMAN, J
    JELLIFFE, RW
    DRUG INTELLIGENCE & CLINICAL PHARMACY, 1980, 14 (09): : 633 - 633